Patent ID: 6136796
Filing Date: 2000-10-24
Classification: A61K,A61P,C07F

Abstract:
A pharmaceutically acceptable prodrug for treating a disease or disorder selected from the group consisting of localized tissue ischemia, stroke, epilepsy, asthma and allergy in a mammal comprising a pharmacologically active caboxylic acid selected from the group consisting of branched-chain aliphatic carboxylic acids, salicylic acids, steroidal carboxylic acids, monoheterocyclic carboxylic acids and polyheterocyclic carboxylic acids, said pharmaceutically active carboxylic acid being covalently bonded to an intracellular transporting adjuvant selected from the group consisting of hydroxy C.sub.2-6 -alkyl esters of lysophosphatidic acids and lysophospholipids, said pharmacologically active compound being effective to treat said disease or disorder, said prodrug being cell membrane permeable, said covalent bond being cleaved in the presence of supranormal intracellular enzyme activity and wherein cleavage of said covalent bond results in selective intracellular activation of therapeutic amounts of the pharmacologically active carboxylic acid with cells having supranormal enzyme activity.